Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214943 | 1.00 | MAPT (0.33) | MAPTABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15250846 | 0.92 | CYP1A2 (0.31) | ABCB1CYP1A2CYP2C9CYP2C19PTPN1 | |
| SCHEMBL16214949 | 0.82 | ABCB1 (0.33) | ABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17863951 | 0.80 | MAPT (0.35) | MAPTABCB1 | |
| SCHEMBL16214951 | 0.74 | ABCB1 (0.32) | ABCB1 | |
| SCHEMBL17359834 | 0.73 | ABCB1 (0.31) | MAPTABCB1 | |
| SCHEMBL17359833 | 0.73 | ABCB1 (0.31) | MAPTABCB1 | |
| SCHEMBL13523562 | 0.73 | PTPN1 (0.36) | MAPTABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13523774 | 0.73 | PTPN1 (0.36) | MAPTABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15095554 | 0.71 | USP2 (0.45) | CYP1A2CYP2C9PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | MAPT 2729/4885ABCB1 733/4885CYP1A2 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.